BioNTech Navigates a Tumultuous Transition: From Vaccine Heights to Cancer Therapy Hopes
BioNTech is shifting focus from COVID-19 vaccines to mRNA-based cancer treatments amid financial challenges. Quarterly EPS dropped to €1.08 from €1.90, outperforming analysts' predictions of €0.407 per share. Revenue fell…